---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Pharmacodynamics"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Pharmacodynamics. Topics: Classical pathway inhibition in healthy volunteers: phase 1; In vitro affinity and potency compared with riliprubart; Restoration of nerve conduction velocity in an in vitro CIDP model; Pharmacokinetic, pharmacodynamic, and immunogenicity assessments in CAPTIVATE. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Classical pathway inhibition in healthy volunteers: phase 1

> “DNTH103 has demonstrated deep and sustained complement inhibition in healthy volunteers DNTH103 demonstrated a ~60-day half-life and IC90 of 87 µg/mL”
> “Safety, PK, and PD measured by percent classical pathway inhibition quantified in each cohort”
> “DNTH103 Phase 1 data confirms potent inhibition of the classical pathway as a Q2W S.C. injection ~60-day half-life IC90 calculated at 87 µg/mL”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.2-2"></a>

### In vitro affinity and potency compared with riliprubart

| Assay | DNTH103 | Riliprubart |
| --- | --- | --- |
| Binding affinity to human active C1s, KD (KinExa) | “9pM” | “75pM” |
| Binding affinity to human active C1s, KD (SPR) | “8pM” | “35pM” |
| C4 cleavage by human active C1s, IC90 (nM) | “0.47” | “3.69” |
| Wieslab classical pathway assay in human serum, IC90 (μg/mL) | “0.45” | “5.4” |
| CH50 assay of RBC lysis in human serum, IC90 (μg/mL) | “98” | “668” |
| Liposome lysis in human serum, IC90 (μg/mL) | “14.7” | “39.8” |

Source: [Katzberg et al. (2024)](https://investor.dianthustx.com/static-files/f8df567c-6c87-4c24-9195-34850953731f)

> “DNTH103 consistently outperforms riliprubart* in affinity and potency when compared head-to-head across multiple in vitro experiments”
> “Riliprubart is produced using sequence from patent WO2018071676A1”

Source: [Katzberg et al. (2024)](https://investor.dianthustx.com/static-files/f8df567c-6c87-4c24-9195-34850953731f)

<a id="topic-2.1.2.6.2-3"></a>

### Restoration of nerve conduction velocity in an in vitro CIDP model

> “Serum from three CIDP patients was evaluated in a validated commercially available in vitro CIDP model”
> “Endpoint: DNTH103 was evaluated at two doses, results were characterized relative to baseline conduction velocity determined in sera from healthy volunteers (n=3)”
> “DNTH103 completely restores conduction velocity across the axons of human motor neurons in the presence of pathological autoantibodies from CIDP patient sera”
> “Three sera were positive for NF155 (autoantibody test panel: NF155, NF186, CNTN1, CASPR1)”

Source: [Katzberg et al. (2024)](https://investor.dianthustx.com/static-files/f8df567c-6c87-4c24-9195-34850953731f)

<a id="topic-2.1.2.6.2-4"></a>

### Pharmacokinetic, pharmacodynamic, and immunogenicity assessments in CAPTIVATE

> “Safety and tolerability, including adverse events • Pharmacokinetics and pharmacodynamics • Immunogenicity of claseprubart • Assess effect of claseprubart on biomarkers of disease activity”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
